Tranexamic acid has a pharmaceutical history – it’s been used orally and intravenously as an antifibrinolytic agent (it reduces bleeding by stabilising blood clots). Its application in dermatology came from observations that oral tranexamic acid used in surgery coincidentally reduced melasma in patients who had it. That observation led to topical formulations, and the research has been building since.
The brightening mechanism is distinct from most other actives. Tranexamic acid blocks the interaction between keratinocytes and melanocytes by inhibiting plasminogen activation. Plasmin (activated from plasminogen) stimulates keratinocytes to release mediators that activate nearby melanocytes. By blocking this signalling pathway, tranexamic acid reduces the UV-induced and inflammation-triggered melanin production at its source – it’s acting on the communication channel between cells rather than on melanin synthesis directly.
This mechanism makes it particularly effective for post-inflammatory hyperpigmentation (PIH) – discolouration that follows acne, eczema flares, or any inflammatory insult to the skin. Vitamin C and alpha arbutin act on tyrosinase activity. Tranexamic acid acts on the upstream signalling that triggers tyrosinase activity in the first place. Used together, they cover different points in the same pathway.
Topical concentrations of 2-5% show consistent results in clinical studies for melasma and PIH. It’s stable across a wide pH range and doesn’t sensitise the skin – two advantages over some other brightening actives.
It pairs naturally with niacinamide (which blocks melanosome transfer) and SPF (which prevents the UV triggers that initiate the signalling cascade in the first place). If you’re addressing hyperpigmentation seriously, these three together address three different points in the same pathway.